2016 - Fellow of the Royal Society, United Kingdom
The scientist’s investigation covers issues in Genetics, Multiple sclerosis, Genome-wide association study, Immunology and Single-nucleotide polymorphism. His Allele, Linkage disequilibrium, Locus, Gene and Human leukocyte antigen study are his primary interests in Genetics. His Multiple sclerosis research incorporates themes from Internal medicine, Adverse effect, Pathology, CLEC16A and Alemtuzumab.
His research in Genome-wide association study intersects with topics in SNP, Allele frequency, Genetic association, Missing heritability problem and Genetic architecture. His study in Allele frequency is interdisciplinary in nature, drawing from both Population stratification, Nonsynonymous substitution, Case-control study, Human genetics and CDKN2BAS. His work in the fields of Single-nucleotide polymorphism, such as International HapMap Project and TCF7L2, intersects with other areas such as TRNA Methyltransferases, Posterior probability and Bayes' theorem.
Multiple sclerosis, Genetics, Neuroscience, Immunology and Linkage disequilibrium are his primary areas of study. His Multiple sclerosis study combines topics in areas such as Disease, Pathology, Alemtuzumab, Remyelination and Allele. His work in Single-nucleotide polymorphism, Genome, Microsatellite, Gene and Genome-wide association study is related to Genetics.
A large part of his Single-nucleotide polymorphism studies is devoted to SNP. His research combines Genetic association and Genome-wide association study. His studies examine the connections between Immunology and genetics, as well as such issues in Cell biology, with regards to Cellular differentiation and Embryonic stem cell.
Alastair Compston mainly focuses on Multiple sclerosis, Alemtuzumab, Relapsing remitting, Family medicine and Queen. Multiple sclerosis is a primary field of his research addressed under Immunology. His Immunology study combines topics from a wide range of disciplines, such as Cell biology, Neural stem cell and Oligodendrocyte.
His study explores the link between Alemtuzumab and topics such as Adverse effect that cross with problems in Expanded Disability Status Scale and Rash. His Relapsing remitting study which covers Disease activity that intersects with Relapse rate. His Internal medicine research includes themes of Surgery and Oncology.
Alastair Compston focuses on Multiple sclerosis, Genome-wide association study, Genetics, Alemtuzumab and Genetic association. His Multiple sclerosis study necessitates a more in-depth grasp of Immunology. His work deals with themes such as SNP, Linkage disequilibrium, Genetic architecture, Missing heritability problem and Epilepsy, which intersect with Genome-wide association study.
Genetics is a component of his Gene, Allele frequency, Allele, Locus and Tyrosine kinase 2 studies. His Genetic association study deals with the bigger picture of Single-nucleotide polymorphism. His Single-nucleotide polymorphism research incorporates elements of Amyotrophic lateral sclerosis and Genetic predisposition.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
Paul R. Burton;David G. Clayton;Lon R. Cardon;Nick Craddock.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Risk alleles for multiple sclerosis identified by a genomewide study.
David A. Hafler;Alastair Compston;Stephen Sawcer;Mark J. Daly.
The New England Journal of Medicine (2007)
Genome-wide association study identifies eight loci associated with blood pressure
Christopher Newton-Cheh;Christopher Newton-Cheh;Toby Johnson;Toby Johnson;Vesela Gateva;Martin D. Tobin.
Nature Genetics (2009)
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
Paul R Burton;David G Clayton;Lon R Cardon;Nick Craddock.
Nature Genetics (2007)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
Philip L De Jager;Philip L De Jager;Xiaoming Jia;Joanne Wang;Paul I W de Bakker.
Nature Genetics (2009)
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls
Nick Craddock;Matthew E. Hurles;Niall Cardin;Richard D. Pearson.
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
Stephen Sawcer;Hywel B. Jones;Robert Feakes;Julia Gray.
Nature Genetics (1996)
Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A
Sergey Nejentsev;Joanna M. M. Howson;Neil M. Walker;Jeffrey Szeszko.
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
Peter Connick;Madhan Kolappan;Charles Crawley;Daniel J Webber.
Lancet Neurology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: